Show simple item record

dc.contributor.authorImseeh, G
dc.contributor.authorGiles, SL
dc.contributor.authorTaylor, A
dc.contributor.authorBrown, MRD
dc.contributor.authorRivens, I
dc.contributor.authorGordon-Williams, R
dc.contributor.authorTer Haar, G
dc.contributor.authordeSouza, NM
dc.identifier.citationInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2021, 38 (1), pp. 623 - 632en_US
dc.description.abstract<h4>Objective</h4>To document longitudinal symptom, quality-of-life and imaging response in patients with recurrent gynecological tumors treated with magnetic resonance guided high intensity focused ultrasound (MRgHIFU), and compare changes in patients with intra- versus extra-pelvic lesions.<h4>Methods</h4>Eleven symptomatic patients with painful recurrent gynecological tumors were treated with MRgHIFU (Profound Sonalleve) in a prospective single center study (NCT02714621). Pain scores, analgesic intake and quality-of-life metrics, whole tumor volume, and perfused tumor volume from Gadolinium-enhanced T1W imaging documented before and up to 90 days after treatment were compared between patients with intra- and extra-pelvic tumors.<h4>Results</h4>Two of five patients with intra-pelvic and three of six patients with extra-pelvic tumors were classified as responders (>2 point reduction in NRS pain score without analgesia increase or <i>a</i> > 25% reduction in analgesic use). Cohort reductions in worst pain scores were not significant for either group. Emotional functioning for the whole cohort improved, although physical functioning did not. Ablative thermal temperatures were achieved in three patients with extra-pelvic tumors, but in none whose tumors were intra-pelvic. Pain response did not correlate with thermal dose. Tumor volume increased by 18% immediately post-treatment in the extra-pelvic but not in the intra-pelvic group. Ratio of perfused to whole lesion volume decreased by >20% by day 30 in extra-pelvic, but not intra-pelvic tumors although at day 30 both extra-pelvic and intra-pelvic tumors increased in volume.<h4>Conclusion</h4>MRgHIFU treatments can be delivered safely to patients with recurrent gynecological tumors. Extra-pelvic tumors responded better than intra-pelvic tumors and showed immediate swelling and reduction in perfused volume by day 30.en_US
dc.format.extent623 - 632en_US
dc.titleFeasibility of palliating recurrent gynecological tumors with MRGHIFU: comparison of symptom, quality-of-life, and imaging response in intra and extra-pelvic disease.en_US
dc.typeJournal Article
dc.relation.isPartOfInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Groupen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Therapeutic Ultrasound
pubs.embargo.termsNot knownen_US
icr.researchteamMagnetic Resonance
icr.researchteamTherapeutic Ultrasound
dc.contributor.icrauthorTer Haar, Gailen_US
dc.contributor.icrauthordeSouza, Nanditaen_US
dc.contributor.icrauthorGiles, Sharonen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as